TG Therapeutics Inc. stocks have been trading up by 9.98 percent after highly positive coverage of its lymphoma treatment.
Live Update At 11:32:05 EDT: On Wednesday, June 03, 2026 TG Therapeutics Inc. stock [NASDAQ: TGTX] is trending up by 9.98%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TG Therapeutics, trading under ticker TGTX, has been acting like a high‑beta grinder on the chart. Over the last several sessions, TGTX has largely held in the high‑30s to low‑40s, with the latest close around $40.30 after a morning push from a $38 handle. Intraday action shows a steady bid, with dips toward $40 getting bought and the stock grinding higher through the low‑$40 range before cooling off. That tells traders there is real demand supporting this level.
Fundamentally, TGTX printed Q1 2026 revenue of $204.9M, a small beat versus roughly $200M expectations. EPS at $0.12 missed Street numbers in the high‑$0.20s to low‑$0.30s, but the company’s margins are eye‑catching for a commercial‑stage biotech, with gross margin above 90% and profit margin north of 60%. The P/E around 13 and price‑to‑sales near 8.2 suggest the market already prices in growth, yet not at nosebleed levels for a fast‑growing MS name.
The balance sheet for TG Therapeutics looks liquid, with a current ratio near 5.8 and cash of about $442M against long‑term debt around $752M. That gives TGTX room to keep funding BRIUMVI expansion and clinical work without constant capital raises, which matters for traders watching dilution risk.
Why Traders Are Watching TGTX Right Now
TGTX is on radar because the story is shifting from “can they sell BRIUMVI?” to “how big can this get?” Q1 revenue at $204.9M gave traders proof that demand is real. The headline snag was the $0.12 EPS miss versus expectations up to $0.33, which triggered some knee‑jerk selling. But management didn’t flinch. Instead, TG Therapeutics raised full‑year U.S. BRIUMVI guidance to $885–900M and lifted 2026 global revenue outlook to about $925M.
For active traders, that’s classic expectations‑reset territory. The short‑term crowd focuses on the EPS miss, while bigger money starts modeling a steeper revenue curve. When a commercial biotech like TGTX raises guidance sharply, the underlying script is usually, “our launch is ahead of plan.”
Clinical news is backing that up. The Phase 3 ENHANCE trial showed a single 600 mg Day 1 BRIUMVI infusion is bioequivalent to the current split‑dosing start, with similar safety and MRI outcomes and hints of fewer infusion reactions. That kind of simplification matters in the real world. A one‑day start is easier for patients, easier for infusion centers, and easier for neurologists to adopt. TG Therapeutics plans a supplemental BLA in 2H 2026, setting up a clear regulatory catalyst.
On top of that, a pooled post‑hoc analysis from the ULTIMATE I & II trials found BRIUMVI delivered better clinical and MRI results than teriflunomide in treatment‑naive relapsing MS, especially early in disease. That arms TGTX sales reps with a powerful message and supports the idea that BRIUMVI can fight for “front‑line” share, not just scraps. H.C. Wainwright leaning in with a higher $70 target and a reiterated Buy rating reinforces that the Street is taking the long view.
Traders also have a near‑term calendar watch: TG Therapeutics will speak at the Goldman Sachs 47th Annual Healthcare Conference, which often generates headlines and fresh color on guidance and strategy.
More Breaking News
- MSAI Stock Whipsaws As Traders Weigh Cash Versus Losses
- GNTA Stock Sees Volatile Spike As Traders Eye Key Levels
- SOFI Stock Slides As Legal, Accounting Scrutiny Intensifies
- LAC Stock Grinds Higher As Thacker Pass Spending Ramps
Conclusion
For TGTX, the tape and the fundamentals tell the same basic story: this is a real commercial growth name with some expected volatility. The stock has pulled back from the mid‑$40s into the high‑$30s and low‑$40s, but buyers keep stepping in near $38–$39, creating a tradable range. Earnings brought noise around the EPS miss, yet revenue strength and raised BRIUMVI guidance argue the core business is tracking ahead of early expectations.
The clinical package around BRIUMVI gives TG Therapeutics something many small‑cap biotechs never achieve: differentiated data versus a known MS drug, plus a convenience upgrade if the single‑infusion ENHANCE regimen wins approval. Analyst support, highlighted by H.C. Wainwright’s $70 target, adds another layer of confidence for traders who track Street sentiment as a secondary indicator.
As always, this is where discipline matters. TGTX is a momentum‑driven biotech, not a slow‑moving utility. That means wide ranges, sharp morning moves, and occasional air pockets on headlines. Tim Sykes always tells traders to “trade the pattern, not the story,” and TGTX fits that mold perfectly right now. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” The story is strong, the chart is volatile, and the edge comes from planning your risk, cutting losses fast, and letting only the best setups play out. This analysis is for educational and research purposes only, not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply